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O B J E C T I V E S We sought to determine the antiatherosclerotic properties of pioglitazone using
multimethod noninvasive imaging techniques.
B A C KG ROUND Inﬂammation is an essential component of vulnerable or high-risk atheromas.
Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, possesses potent anti-
inﬂammatory properties. We aimed to quantify noninvasively the anti-inﬂammatory effects of pioglita-
zone on atheroma using 18F-ﬂuorodeoxyglucose (18F-FDG) positron emission tomography (PET)/
computed tomography (CT) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI).
METHOD S Atherosclerotic plaques were induced in the aorta of 15 New Zealand white rabbits by
a combination of a hyperlipidemic diet and 2 balloon endothelial denudations. Nine rabbits continued
the same diet, whereas 6 rabbits received pioglitazone (10 mg/kg orally) in addition to the diet. Twelve
animals underwent 18F-FDG-PET/CT, and 15 animals underwent DCE-MRI at baseline, 1 month, and 3
months after treatment initiation. Concomitantly, serum metabolic parameters were monitored. After
imaging was completed, aortic histologic analysis and correlation analysis were performed.
R E S U L T S The 18F-FDG-PET/CT imaging detected an increase in average standardized uptake value in the
control group (p  0.01), indicating progressive inﬂammation, whereas stable standardized uptake values were
observed in the treatment group, indicating no progression. The DCE-MRI analysis detected a signiﬁcant decrease
in the area under the curve for the pioglitazone group (p  0.01). Immunohistologic examination of the aortas
demonstrated a signiﬁcant decrease in macrophage and oxidized phospholipid immunoreactivity in the
pioglitazone group (p 0.04 and p 0.01, respectively) with respect to control animals, underlining the imaging
results. Serummetabolic parameters showed no difference between groups. Strong positive correlations between
standardized uptake value and macrophage density and between area under the curve and neovessels were
detected (r2  0.86 and p  0.0001, and r2  0.66 and p  0.004, respectively).
CONC L U S I O N S Both 18F-FDG-PET/CT and DCE-MRI demonstrate noninvasively the anti-inﬂammatory
effects of pioglitazone on atheroma. Both imaging methods seem suited to monitor inﬂammation in
atherosclerosis. (J Am Coll Cardiol Img 2011;4:1100–9) © 2011 by the American College of Cardiology
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1101ardiovascular disease remains the major cause
of morbidity and mortality worldwide (1),
despite the widespread use of low-density li-
poprotein cholesterol-lowering therapies. In-
flammation, mainly promoted by oxidized lipids in
the vessel wall, plays a critical role in all stages of
atherosclerosis, but is crucial in plaque rupture and
thrombosis, which causes most acute coronary
See page 1119
events (2,3). Vulnerable plaques are characterized
by a relatively large lipid core, a thin fibrous cap,
and an abundance of inflammatory cells (especially
macrophages) accompanied by neovascularization (4).
Currently, therapies targeting reversal cholesterol
transport and inflammation, in particular recombi-
nant high-density lipoprotein therapeutics and var-
ious nuclear receptor agonists, are being developed
(5). However, their translation into clinical practice
has been difficult because of the lack of clinical
outcome studies and validated surrogate endpoints (6).
The peroxisome proliferator-activated receptor
gamma (PPAR-) belongs to a nuclear receptor
uperfamily of ligand-dependent transcription fac-
ors. Different cells involved in the pathogenesis of
therosclerosis, such as endothelial cells, smooth
uscle cells, T-lymphocytes, dendritic cells, and
ainly macrophages, express PPAR- receptor
(7,8). Synthetic PPAR- receptor ligands, thiazo-
idinediones, are used in clinical practice as oral
ntidiabetic agents. Besides their antidiabetic prop-
rties, thiazolidinediones have demonstrated in
nimal studies potent antiatherosclerotic effects
y inhibiting the formation of atherosclerotic
laques (9,10). However, some thiazolidinedio-
es may increase the risk of myocardial infarction
11). Pioglitazone, in contrast, in the large clinical
econdary prevention PROspective pioglitAzone
linical Trial In macroVascular Events trial (more
han 5,000 subjects), demonstrated a significant
From the *Translational and Molecular Imaging Institute, Imaging
Science Laboratories, Mount Sinai School of Medicine, New York, New
York; ‡Department of Radiology, Mount Sinai School of Medicine, New
York, New York; §Division of Cardiovascular Medicine, University of
Cambridge, Cambridge, United Kingdom; Biostatistics Shared Research
Facility, Department of Community and Preventive Medicine, Mount
Sinai School of Medicine, New York, New York; ¶Vascular Medicine
Program, University of California San Diego, La Jolla, California;
#Department of Cardiology, New York University School of Medicine,
New York, New York; **Biomedical NMR, Department of Biomedical
Engineering, Eindhoven University of Technology, Eindhoven, the
Netherlands; †The Zena and Michael A. Wiener Cardiovascular Institute
and Marie-Josée and Henry R. Kravis Cardiovascular Health Center,
Mount Sinai Hospital, New York, New York; and the ††Centro Nacionaleduction of all-cause mortality, myocardial infarc-
ion, and stroke in a diabetic patient population
12). Two subsequent large trials (CHICAGO
Carotid Intima-Media Thickness in Atherosclero-
is Using Pioglitazone] and PERISCOPE [Piogli-
azone Effect on Regression of Intravascular Sono-
raphic Coronary Obstruction Prospective Evaluation])
howed decreased progression of carotid intima-
edia thickness (as assessed by surface and intra-
ascular ultrasounds) after 18 months of treatment
ith pioglitazone. These 2 studies confirmed the
ignificant vascular benefits of pioglitazone and
ighlighted the potential role of imaging in tracking
he progression of disease or its regression on
herapeutic intervention. However, the
maging techniques used in these studies
o not give any information regarding
hanges in vascular inflammation induced
y pioglitazone, which may help to iden-
ify responsive patients much before ana-
omical changes become apparent. Nonin-
asive imaging techniques targeted toward
uantifying inflammation, macrophage
ontent, and neovascularization of athero-
clerotic vessels represent an attractive
linical tool. In an ideal scenario, such
echniques would allow an accurate read-
ut of vessel wall inflammation, delineat-
ng cardiovascular risk, guiding therapeu-
ic decisions, and defining the role of novel
reatments, and therefore may aid in risk
tratification and may provide surrogate
herapeutic endpoints (13). Recently, a
tudy in mice showed that noninvasive
ptical molecular imaging techniques can
etect changes in inflammation on piogli-
azone treatment (14). However, the tech-
iques used in these studies cannot be
pplied in a clinical setting because of the
imited depth penetration possible with
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1102optical imaging. 18F-fluorodeoxyglucose (18F-
FDG) positron emission tomography (PET)/
computed tomography (CT) and dynamic contrast-
enhanced (DCE) magnetic resonance imaging
(MRI) are noninvasive, clinically available tech-
niques and recently have been validated as indica-
tors of vascular inflammation: 18F-FDG-PET/CT
etected vascular macrophage content and DCE-
RI detected neovascularization (15–18). In this
tudy, we applied 18F-FDG-PET/CT and DCE-
MRI to characterize vascular inflammation and
neovascularization and its changes during pioglita-
zone treatment in a rabbit model of atherosclerosis.
M E T H O D S
Animal model. Fifteen New Zealand white rabbits
(Charles River Laboratories, Inc., Wilmington,
Massachusetts) at the age of 3 months (weight: 3.0 
0.1 kg) were fed a diet containing 0.3% cholesterol
and 4.7% coconut oil for 3 months and 0.15%
cholesterol and 4.7% coconut oil thereafter. The
development of atherosclerosis was enhanced fur-
ther with a double balloon injury to the abdominal
aorta at weeks 2 and 6 (19). At 4 months, the
animals were divided into 2 groups (control: n  9,
treatment: n  6). The treatment group received
pioglitazone (10 mg/kg body weight) (20) mixed
with the high-fat diet for 3 months (Fig. 1). Three
0
Lipid Profile PET / CT
DCE-MRI
MC-MRI
Lipid Profile
P
D
M
Lip
Balloon injury at 2 and 6
weeks (n = 15)
High Cholesterol Diet
Baseline 1
3 4
Figure 1. Study Design
Atherosclerosis was induced in 15 New Zealand white rabbits throu
After 4 months of the diet, the ﬁrst imaging scans and lipid proﬁles
a control group and a pioglitazone group. After a total of 5 month
ing) were performed. The ﬁnal imaging scans and lipid proﬁles wer
then were killed immediately and tissue analysis was performed. DC
MC-MRI  multicontrast-magnetic resonance imaging; PET/CT  poage-matched animals on a chow diet served as
nonatherosclerotic controls. Diets were prepared by
Research Diets Inc. (New Brunswick, New Jersey).
All procedures were performed under anesthesia by
intramuscular injection of ketamine (20 mg/kg)
(Fort Dodge Animal Health, Overland Park, Kan-
sas) and xylazine (5 mg/kg) (Bayer AG, Le-
verkusen, Germany). The protocol was approved by
the Mount Sinai School of Medicine Institute
Animal Care and Use Committee.
Serum analysis and fast protein liquid chromatography.
Blood was collected from 12-h fasting animals at
baseline, 4, 5, and 7 months after high-cholesterol diet
and was separated into serum per standard protocols
(21). Serum samples were analyzed using commercial
kits for cholesterol, triglycerides, glucose, and insulin.
In addition, pooled serum at baseline and after 3
months of pioglitazone treatment was subjected to fast
protein liquid chromatography.
Immunohistologic analysis. Macrophages were de-
tected on adjacent slices by standard immunohisto-
chemistry techniques. The total macrophage-rich
(RAM-11–positive) area was quantified digitally as
fraction of the intimal-media area (i.e., macrophage
density) per slice and was expressed as the average
macrophage density per animal. Similarly, the areas for
smooth muscle actin, apolipoprotein B-100, and oxi-
dized phospholipids were evaluated. Neovessels were
Time (Months)
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7
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a combination of double-balloon injury and high cholesterol diet.
re performed (baseline), and animals were divided into 2 groups:
other round of imaging scans and lipid proﬁles (1-month imag-
rformed after a total of 7 months (3-month imaging). All animals
RI  dynamic contrast-enhanced magnetic resonance imaging;
on emission tomography/computed tomography.ET / 
CE-M
C-M
id Pr
 Mon
5
gh
we
s, an
e pe
E-M
i
c
a
o
i
M
p
e
n
t
i
r
w
w
p
b
a
m
s
P
t
l
c
t
a
l
e
w
e
t
r
t
m
i
i
s
p
v
A
l
t
o
i
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 4 , N O . 1 0 , 2 0 1 1
O C T O B E R 2 0 1 1 : 1 1 0 0 – 9
Vucic et al.
Pioglitazone Modulates Vascular Inflammation
1103detected on a single DCE image matched section with
an anti-CD31 antibody, as previously described (17).
18F-FDG-PET/CT. Six rabbits from each group were
maged using a combined PET/CT scanner (Dis-
overy LS, GE Healthcare). The PET images were
cquired for 10 min, 3 h after intravenous injection
f 18F-FDG (37 MBq [1 mCi/kg]) (19). The
images were acquired in 3-dimensional mode, and
the acquisition covered the area from the dia-
phragm to the iliac bifurcation. A Fourier iterative
reconstruction of the PET data was used. In addi-
tion to a PET scan, a non–contrast-enhanced CT
scan was obtained for each rabbit on the same
scanner for attenuation correction and anatomical
localization of the PET signal. The final recon-
structed slice thickness was 4.25 mm.
PET/CT analysis. The PET/CT data were displayed
n 3 orthogonal planes on a GE Xeleris workstation.
aximal standard uptake values (SUVmax) and
mean standard uptake values (SUVmean) were re-
corded on contiguous axial slices of the aorta between
the left renal artery and the iliac bifurcation (average
number of slices: 13.6) from regions of interest en-
compassing the vessel wall. Results were expressed as
the average SUVmean of the aorta per animal.
Anatomic and DCE-MRI. Nine control and 6
ioglitazone-treated rabbits were imaged under an-
sthesia using a 1.5-T MRI system (Siemens So-
ata, Siemens Medical Solutions) and a conven-
ional knee coil. Sequential axial, 3-mm thick
mages of the aorta were obtained from the left
enal artery to the iliac bifurcation using T1-
eighted, T2-weighted, and PD (proton density)-
eighted imaging sequences. The DCE-MRI was
erformed on 1 selected axial slice using a black
lood turbo spin echo sequence previously validated
gainst histologic analysis (17).
Anatomic multicontrast-MRI and DCE-MRI analysis.
Average vessel wall area of the aorta between the
left renal artery and iliac bifurcation was quantified
on contiguous slices by manual tracing on T2-
weighted images (VesselMass Software, Leiden
University Medical Center). Then, DCE-MRI
quantified the change of signal intensity in a region
of interest including the entire atherosclerotic
plaque during the injection of the contrast agent
with a custom-made Matlab (The MathWorks
Inc., Natick, Massachusetts) program. The area
under the curve (AUC) was quantified at 1 min
(AUC1min) and at 2 min (AUC2min) after injection
of contrast agent by numerical integration (17).
Statistical analysis. Numeric values are expressed asean  SD. A p value 0.05 was consideredtatistically significant. Continuous DCE-MRI and
ET outcomes were modeled as linear functions of
ime for both treatment and control groups. A
inear mixed model with random intercepts and
ompound symmetric covariance structure was used
o estimate the regression equations for treatment
nd control groups while accounting for the corre-
ation between repeated measurements made on
ach rabbit (22). The models for PET outcomes
ere weighted by the number of slices analyzed in
ach animal. To test for differences among the
reatment and control groups estimated by linear
egression equations, an interaction term between
reatment group and time was included in each
ixed model along with both main effects. If the
nteraction term was found to be statistically signif-
cant, then pairwise comparisons of treatment group
lopes were estimated. All statistical analyses were
erformed using Proc Mixed in SAS software
ersion 9.2 (SAS Institute, Cary, North Carolina).
verage macrophage density per animal was corre-
ated with average animal SUVmax or AUC1min of
he corresponding animal. Neovessels were counted
n a single section, were matched to the DCE-MRI
maged slice, and were correlated with AUC1min or
Table 1. Animal Characteristics
Control
(n  9)
PIO
(n  6) p Value
Weight (kg)
t  4 months 3.42 0.29 3.32 0.33 0.52
t  5 months 3.47 0.31 3.29 0.40 0.32
t  7 months 3.42 0.38 3.40 0.28 0.90
Total cholesterol (mg/dl)
t  4 months 1,099 291 1,220 197 0.35
t  5 months 1,158 282 1,143 126 0.91
t  7 months 1,154 230 1,278 159 0.27
Triglycerides (mg/dl)*
t  4 months 147 126 165 168 0.87
t  5 months 113 95 102 65 0.84
t  7 months 172 163 105 17 0.52
Glucose (mg/dl)
t  4 months 152 31 132 25 0.29
t  5 months 178 40 156 43 0.32
t  7 months 180 47 170 47 0.67
Insulin (ng/dl)
t  4 months 0.52 0.37 0.49 0.45 0.91
t  5 months 0.44 0.39 0.32 0.05 0.53
t  7 months 0.23 0.13 0.21 0.06 0.79
Data for weight and fasting values for total cholesterol, triglycerides, glucose,
and insulin are presented for the control and pioglitazone (PIO) groups in
separate columns. Values of p between the control and PIO groups were
determined with a Student t test and are shown in a separate column.
Individual data except p values are represented as mean  SD. *Indicated
nonfasting.
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1104average SUVmax of the corresponding animal. The
UC1min and average SUVmax from corresponding
nimals were correlated. All correlations were mea-
ured using Pearson testing after normality of the
ata was established. All histologic data, animal char-
cteristics data, and nonlinear regression imaging data
ere analyzed with a 2-tailed Student t test.
Power analysis. Retrospective power was computed
using SAS Proc Mixed as previously described (23).
R E S U L T S
Study design, animal characteristics, and serum analysis.
The study design is depicted in Figure 1. After 4
months of a high-cholesterol diet, significantly
elevated total cholesterol levels were observed (Table 1).
here were no significant baseline differences in total
holesterol between the control and pioglitazone-treated
roups before treatment initiation (Table 1). There were
no statistically significant differences in fasting se-
rum glucose or insulin levels and in nonfasting
triglycerides in either group throughout the study.
Both groups had nearly identical weights through-
out the study (Table 1). Fast protein liquid chro-
matography at baseline and after 3 months revealed
no significant differences in lipoprotein profiles
A
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Figure 2. Regression Analysis
(A) Correlation between the maximum standard uptake value (SUV
rophage density (stained area/intimal area) from histologic staining
(AUC1min) generated from DCE-MRI imaging and neovessel count p
count per histologic section. (D) Correlation between mean AUC1m
between SUVmax and mean AUC1min. Solid lines  regression line; dashafter pioglitazone treatment (Online Appendix Fig-
ure 1).
SUV correlates with tissue macrophage content and
AUC correlates with neovascularization. We corre-
lated the SUVmax and AUC1min against macro-
hage density and neovessel counts, respectively,
nd found a strong positive correlation (r2  0.86
and p  0.0001, and r2  0.66 and p  0.004,
espectively) (Figs. 2A and 2B), consistent with the
esults of previous studies (17,24). No strong cor-
elation was found between SUVmax and neovessel
ount and between AUC1min and macrophage den-
sity (r2  0.09 and p  0.37, and r2 0.19 and p
0.18, respectively) (Figs. 2C and 2D). The SUVmax
and AUC1min values did not correlate strongly (r
2
.17, p  0.18) (Fig. 2E).
Pioglitazone arrests inﬂammation progression as
assessed by 18F-FDG-PET/CT. On completion of base-
ine imaging, animals were divided into matched
roups, 1 control group and 1 treatment group,
ith both groups displaying similar baseline SUVmax
values (0.64  0.05 and 0.62  0.12, p  0.70)
Figs. 3A and 3C and bar graph). The SUV versus
ime slope for the control group is positive, there-
ore indicating an increase in SUVmax (p  0.10)
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1105and SUVmean (p  0.02) over time. However, the
SUV versus time slope for the treatment group was
not statistically different from 0 (SUVmax: p 0.70,
SUVmean: p  0.92), indicating no significant
rogression in plaque inflammation. Comparison of
he 2 slopes indicated a trend toward significance
SUVmax: p  0.15, SUVmean: p  0.1). Compar-
ison of SUV values between the 2 groups at 1 and
3 months showed significant differences (p  0.05)
for both SUVmax and SUVmean. Nonatherosclerotic
ged-matched animals on chow diet show minimal
UV values.
Pioglitazone decreases neovascularization as assessed
by DCE-MRI. In analogy to the 18F-FDG-PET/CT
xperiments, we applied DCE-MRI to assess in-
ammation and neovascularization in atheroscle-
otic plaques (Fig. 4). The AUC versus time slope
or the control group was not statistically different
rom 0 for AUC measures (AUC1min: p  0.33,
AUC2min: p  0.18). The AUC versus time slope
or the treatment group was negative and signifi-
antly different from 0 for all AUC measures (p 
Figure 3. 18FDG-PET/CT
(A to F) Coronal PET images through the abdominal aorta (white a
line control and baseline pioglitazone (PIO) groups. (B and E) 1-mo
and PIO groups. On the right, 2 bar graphs summarize the changes
(1M), and 3 months (3M) for both groups. Right-most bar shows va
as mean  SD. *p  0.05 when comparing control and PIO groups
units. Abbreviations as in Figures 1 and 2..01). A trend toward significance was found when aomparing the control and treatment groups slopes
AUC1min: p  0.06, AUC2min: p  0.09). There
as a significant difference between baseline and
-month AUC values in the treatment group
AUC1min: p  0.01).
Pioglitazone has no effect on vessel wall area as
assessed by multicontrast-MRI. Multicontrast-MRI
howed no significant changes in aortic wall area in
ither group during the study (Fig. 5).
Pioglitazone decreases plaque macrophages and
oxidized phospholipids. Macrophage staining at the
nd of the imaging study revealed a significant de-
rease in macrophage density within the pioglitazone
roup compared with the control group (0.25  0.05
rbitrary unit [AU] and 0.32 0.02 AU, respectively,
 0.04) (Figs. 6 and 7). A trend toward lower
polipoprotein B density was detected in the pioglita-
one group compared with the control group (0.28
.03 AU and 0.34 0.07 AU, respectively, p 0.12)
(Figs. 6 and 7). Pioglitazone treatment resulted in a
1% reduction in the oxidized phospholipid density
ompared with the control group (0.086 0.026 AU
heads) from 1 representative animal per group. (A and D) Base-
control and 1-month PIO groups. (C and F) Three-month control
(top) SUVmax and (bottom) SUV mean at baseline (BL), 1 month
for nonatherosclerotic chow-fed animals. Values are represented
ematic slopes are indicated as dashed lines. a.u.  arbitraryrrow
nth
in
lues
. Schnd 0.146 0.045 AU, respectively, p 0.03) (Figs.
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11065 and 6). Average smooth muscle actin density was
dentical between groups (0.24  0.075 AU and
.24  0.078 AU, respectively, p  0.88) (Figs.
and 6). A trend toward lower neovessel content
as observed in the pioglitazone-treated group (p 
.12) (Fig. 6).
Power analysis of 18F-FDG-PET/CT and DCE-MRI. 18F-
FDG-PET/CT determined SUVmax values had
Figure 4. DCE-MRI
(A to F) Single-slice axial T1-weighted MRI scans with color-enco
with insert of the aorta. (A and D) Baseline control and baseline
F) Three-month control and PIO groups. Warm colors (orange to
indicate lower AUC values. Bar graph summarizes the changes in th
are represented as mean  SD. *p  0.05 when comparing baseline a
against 0. Schematic slopes are indicated as dashed lines. n.s.  nons
Figure 5. MC-MRI
(A to F) Single-slice axial T2-weighted representative MRI images w
density-weighting. (A and D) Baseline control and PIO groups. (B a
control and PIO groups. Bar graph summarizes the changes in the v
ues are represented as mean  SD. Abbreviations as in Figures 1, 3, and 40% power to detect a difference between individual
roup slopes, 43% power to detect a group effect, and
5% power to detect a time effect. The SUVmean values
ad 40% power to detect a difference between individual
roup slopes, 37% power to detect a group effect, and
5% power to detect a time effect.
DCE-MRI determined AUC1min values had 46%
ower to detect a difference between individual
overlay of the contrast signal at 1 min of the abdominal aorta
groups. (B and E) One-month control and PIO groups. (C and
) indicate higher AUC values and cold colors (green to blue)
C at BL, 1M, and after 3M for the control and PIO groups. Values
M in the PIO group. **p  0.01 when comparing individual slopes
cant. Abbreviations as in Figures 1, 2, and 3.
nsert of the aorta with T2-weighting, T1-weighting, and proton
) One-month control and PIO groups. (C and F) Three-month
l wall area at BL, 1M, and 3M of either the control or PIO group. Val-ded
PIO
red
e AU
nd 3ith i
nd E
esse.
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1107group slopes, 14% power to detect a group effect,
and 87% power to detect a time effect. The AUC2min
values had 39% power to detect a difference between
individual group slopes, 15% power to detect a group
effect, and 92% power to detect a time effect.
D I S C U S S I O N
In this study, we showed significant modulation in
inflammation in aortic plaques of atherosclerotic
rabbits as measured noninvasively by 18F-FDG-
PET/CT and DCE-MRI on treatment with piogli-
tazone. The imaging results are confirmed by the
histologic findings, which show a strong correlation
of macrophage density and neovessel content with
imaging parameters. In addition, this study pro-
vides insight to the diagnostic strengths of both
FDG-PET and DCE-MRI while tracking antiath-
erosclerotic therapeutic intervention.
Previous studies have tested the potential of
FDG-PET to track therapeutic intervention.
Tahara et al. (25) investigated the effect of simva-
statin on plaque inflammation by FDG-PET in the
thoracic aorta of human subjects, whereas Ogawa et
al. (26) investigated the effect of probucol on the
aortic plaques of Watanabe heritable hyperlipid-
emic rabbits. In contrast with the work presented
here, both of these studies showed no significant
increase in FDG uptake in the control groups,
whereas regression of inflammation was demon-
strated by a significant decrease of FDG uptake
over time in the treatment groups. This behavior is
different from what we reported in our study, where
we showed progression of inflammation in the
control group and no change in FDG uptake over
Figure 6. Immunohistologic Findings
Photomicrographs showing immunohistologic staining of the abdo
treatment. Staining (red-brown, red arrowhead) for (A and E) mac
phospholipids (OxPL), and (D and H) smooth muscle actin (SMA) is
side from the tissue. Abbreviation as in Figure 3.time in the treatment group. However, some sig-nificant differences between this study and the ones
described above must be noted. For example, the
dietary differences (dietary restrictions for patients and
chow diet for rabbits as opposed to hyperlipidemic
diet in this study with or without drug, depending on
the group) and the different rabbit model used (Wa-
tanabe heritable hyperlipidemic rabbits versus New
Zealand white rabbits). The only study in the litera-
ture investigating the use of DCE-MRI to track
therapeutic intervention in atherosclerosis shows re-
sults comparable with those presented here, although
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Figure 7. Summary of Immunohistologic Findings
Bar graph showing macrophages (Mac), ApoB, OxPL, and SMA stain
months in vehicle and PIO-treated animals. Insert shows CD-31 stai
neovessels. Values are represented as mean  SD. Individual p valu
between control and PIO groups indicated above bar graph. Abbre
l aorta after 3 months of (A–D) vehicle (control) and (E–H) PIO
ages, (B and F) apolipoprotein B (ApoB), (C and G) oxidized
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1108the time frame of the 2 studies is considerably different
(48 h vs. 3 months of treatment) (27).
In addition to showing the ability of FDG-
PET and DCE-MRI to track therapeutic inter-
vention with pioglitazone, this study sheds light
on the possible complementary role in future
clinical applications of the 2 methods. For exam-
ple, FDG-PET showed an increase in plaque
inflammation in the control group over time,
whereas DCE-MRI measures did not change.
Given the established correlation between FDG-
PET and DCE-MRI with macrophages and
neovessels, respectively, this may reflect a differ-
ence in the change of these histologic variables
over time during plaque progression and may
provide insight to the natural progression of aortic
atherosclerosis in this specific rabbit model. More
natural progression studies are needed to clarify this
behavior and to plan future pre-clinical drug trials.
The difference in FDG-PET and DCE-MRI mea-
sures in the treatment groups (impaired progression
vs. regression) may reflect either the different sensitiv-
ity of the techniques or a different impact of pioglita-
zone on the related histologic variables (macrophages
and neovessels, respectively). In this last case, the
relationship between the 2 imaging techniques may be
different for every new drug study planned with other
therapeutic interventions.
C O N C L U S I O N S
In summary, we demonstrated the effectiveness of2010;55:1283–99. early atherosclerotic lemodulation of vascular inflammation in a rabbit
model of atherosclerosis as evaluated by noninvasive
imaging techniques and validated by histologic
analysis. The 18F-FDG-PET/CT and DCE-MRI
analyses were used in this case as surrogate imaging
markers of vascular inflammation. Both techniques
already are available clinically, which stresses the
translational aspect of this study. Dedicated pro-
spective outcome studies are underway (HRP Ini-
tiative scheduled report in 2011 [28]) that will
clarify the role of plaque inflammation imaging in
patient risk stratification. Furthermore, novel anti-
atherosclerotic therapies are being developed and
their role in clinical practice will need to be estab-
lished. In this sense, the imaging tools described
herein may become potent armaments for improved
drug development and their translation into clinical
practice. Dedicated future clinical studies in nondi-
abetic patient populations will be needed to evaluate
pioglitazone’s effect in atherosclerotic disease.
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